BeOne Medicines Ltd
200 hedge funds and large institutions have $8.47B invested in BeOne Medicines Ltd in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 68 increasing their positions, 70 reducing their positions, and 26 closing their positions.
58% more call options, than puts
Call options by funds: $16.8M | Put options by funds: $10.6M
1% more capital invested
Capital invested by funds: $8.4B → $8.47B (+$63.8M)
0.02% more ownership
Funds ownership: 3.77% → 3.78% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
3% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 70
4% less funds holding
Funds holding: 208 → 200 (-8)
23% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 26
Top Buyers
Top Sellers
| 1 |
Capital International Investors
Los Angeles,
California
|
-$48.3M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$38.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$21.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$14.1M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
-$13.9M |
ONC Hedge Fund Activity: Q3 2023 in Review
200 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q3 2023, worth a combined $8.47B — up 0.76% from $8.4B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ONC and 20 opened new positions — a net loss of 6 holders — while 70 trimmed existing stakes and 68 added.
The largest buyer was Baillie Gifford & Co, adding an estimated $116M. The largest seller was Capital International Investors, cutting an estimated $48.3M.
- 200 institutional investors held BeOne Medicines Ltd (ONC) as of Q3 2023, down from 208 in Q2 2023.
- Funds reported $8.47B of BeOne Medicines Ltd stock for Q3 2023, up 0.76% quarter-over-quarter.
- 20 funds opened new BeOne Medicines Ltd positions in Q3 2023 and 26 closed out, a net change of -6 holders.
- The largest BeOne Medicines Ltd buyer in Q3 2023 was Baillie Gifford & Co, an estimated $116M added.
- The largest BeOne Medicines Ltd seller in Q3 2023 was Capital International Investors, an estimated $48.3M sold.
Based on aggregated 13F filings for Q3 2023.